Cryo-Cell International (OTCMKTS:CCEL) Stock Price Passes Below Two Hundred Day Moving Average of $5.87

Cryo-Cell International, Inc. (OTCMKTS:CCELGet Rating) shares passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $5.87 and traded as low as $4.75. Cryo-Cell International shares last traded at $4.84, with a volume of 1,067 shares traded.

Analyst Ratings Changes

Separately, Maxim Group assumed coverage on shares of Cryo-Cell International in a research note on Monday, August 29th. They set a “buy” rating and a $12.00 price objective on the stock.

Cryo-Cell International Price Performance

The firm’s 50 day simple moving average is $5.46 and its 200 day simple moving average is $5.87. The company has a market cap of $41.24 million, a price-to-earnings ratio of 32.27 and a beta of 0.35.

Cryo-Cell International (OTCMKTS:CCELGet Rating) last announced its quarterly earnings results on Friday, October 14th. The company reported $0.06 EPS for the quarter. Cryo-Cell International had a net margin of 4.34% and a return on equity of 49.62%. The company had revenue of $7.70 million for the quarter.

Insider Activity

In related news, CEO David Portnoy acquired 10,000 shares of the firm’s stock in a transaction dated Monday, November 14th. The stock was acquired at an average cost of $4.80 per share, for a total transaction of $48,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 220,080 shares of the company’s stock, valued at approximately $1,056,384. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders purchased 34,366 shares of company stock worth $167,193 over the last three months. Corporate insiders own 33.80% of the company’s stock.

Hedge Funds Weigh In On Cryo-Cell International

A hedge fund recently raised its stake in Cryo-Cell International stock. Massmutual Trust Co. FSB ADV grew its holdings in shares of Cryo-Cell International, Inc. (OTCMKTS:CCELGet Rating) by 63.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 124,135 shares of the company’s stock after purchasing an additional 48,100 shares during the quarter. Massmutual Trust Co. FSB ADV owned about 1.47% of Cryo-Cell International worth $732,000 as of its most recent filing with the Securities and Exchange Commission. 9.01% of the stock is owned by institutional investors.

About Cryo-Cell International

(Get Rating)

Cryo-Cell International, Inc engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases.

See Also

Receive News & Ratings for Cryo-Cell International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryo-Cell International and related companies with's FREE daily email newsletter.